Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

CELL RESEARCH

SPRINGERNATURE

1. National Key R&D Program of China [2021YFC2300703]
2. National Natural Science Foundation of China [82041025, 92169112, 82002142]
3. Program of Shanghai Academic/Technology Research Leader [20XD1420300]
4. Health and Medical Research Fund [COVID1903010-Project 7]
5. Food and Health Bureau, The Government of the Hong Kong Special Administrative Region
6. Health@InnoHK, Innovation and Technology Commission, the Government of the Hong Kong Special Administrative Region
7. National Program on Key Research Project of China [2020YFA0707500, 2020YFA0707504]
8. Sanming Project of Medicine in Shenzhen, China [SZSM201911014]